Eli Lilly and Company (NYSE:LLY) Stock Rated “Moderate Buy” by Wall Street Brokerages

Eli Lilly and Company (NYSE:LLY) has earned an average recommendation of “Moderate Buy” from the twenty-nine analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, twenty-four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $1,313.43.

LLY has been the topic of several research analyst reports. HSBC raised their price objective on Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a report on Thursday, September 10th. Wall Street Zen lowered Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Saturday. Guggenheim upped their price objective on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a report on Friday, September 18th. Morgan Stanley increased their price target on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Finally, Citigroup lifted their target price on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a report on Wednesday, July 15th.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $1,242.76 on Tuesday. The firm has a market cap of $1.17 trillion, a price-to-earnings ratio of 41.70, a PEG ratio of 1.67 and a beta of 0.46. Eli Lilly and Company has a one year low of $793.82 and a one year high of $1,292.65. The firm’s fifty day moving average is $1,180.34 and its two-hundred day moving average is $1,111.84. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same period in the previous year, the company posted $6.31 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Research analysts expect that Eli Lilly and Company will post 33.56 EPS for the current year.

Insider Buying and Selling

In related news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. This represents a 29.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 in the last ninety days. Company insiders own 0.14% of the company’s stock.

Institutional Trading of Eli Lilly and Company

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $13,522,666,000. Jupiter Topco LLC purchased a new position in Eli Lilly and Company during the 2nd quarter worth approximately $4,667,180,000. Fifth Third Bancorp grew its position in Eli Lilly and Company by 321.3% during the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock worth $1,805,959,000 after purchasing an additional 1,497,423 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Eli Lilly and Company by 353.7% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,550,234 shares of the company’s stock worth $1,425,859,000 after purchasing an additional 1,208,510 shares in the last quarter. Finally, Corient Private Wealth LP acquired a new stake in Eli Lilly and Company during the 2nd quarter valued at $764,116,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong obesity-drug momentum: Analysts expect Lilly’s GLP-1 portfolio to support upcoming third-quarter results. The oral weight-loss treatment Foundayo is also projected to continue gaining market share, and European regulators have recommended its approval—potentially expanding Lilly’s addressable market. Foundayo market-share article
• Positive Sentiment: Pipeline and business-development catalysts: Lilly reported positive Phase 3 results for Omvoh in pediatric ulcerative colitis, with plans to seek a label expansion. It also agreed to pay up to $1.1 billion for drug-delivery technology from Metis TechBio, while forthcoming oncology data could provide additional long-term growth opportunities. Omvoh clinical-trial article
• Positive Sentiment: Financial and analyst support: Lilly’s latest quarterly results substantially exceeded consensus expectations, with revenue rising sharply year over year. RBC Capital Markets also maintained a Buy view, and analysts see potential from manufacturing efficiencies and future therapies such as retatrutide. RBC analyst article

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.